Bicalutamide for female hair loss: how this anti-androgen tablet works, what the trials show and the liver checks
Bicalutamide is a prostate cancer tablet now used off-label by some dermatologists for female pattern hair loss. How it blocks androgen receptors, what the case series and 2025 to 2026 randomised trials found, how it compares with spironolactone and minoxidil, the liver and pregnancy rules, and what makes sense in Malaysia.
Bicalutamide is a tablet that was developed for prostate cancer, yet over the last few years it has become one of the most talked about new options for women with thinning hair. Dermatologists in Australia, Spain, Brazil and India have published case series and, more recently, randomised trials. Women in Malaysia now meet the name in overseas forums and social media, often described as a stronger or "cleaner" alternative to spironolactone. The reality is more measured. Bicalutamide is not licensed for hair loss anywhere, the product information says it is for use in men, it must never be taken in pregnancy, and it needs regular liver blood tests. At the same time, the evidence in women with female pattern hair loss is growing and is genuinely interesting.
This guide explains what bicalutamide is, how it acts on the hair follicle, what each major study found, how it compares with spironolactone, minoxidil and other choices, the safety checks involved, a realistic timeline and what makes sense in Malaysia. It is general information, not personal medical advice. For background, see hair loss in women, female pattern hair loss treatment and spironolactone for female hair loss.
The short answer
Bicalutamide is a non-steroidal anti-androgen. It blocks the androgen receptor, the docking site that DHT and testosterone use to switch on their effects in the hair follicle 1. A 2025 literature review of nine studies covering 494 women found that hair loss severity fell by about 17% to 29% in women with female pattern hair loss who took it for at least 24 weeks, but almost all the women were also using other treatments and most studies were retrospective 2. Randomised trials are mixed: adding 25 mg bicalutamide to oral minoxidil gave no extra density gain over 24 weeks 3, while 50 mg did slightly better than spironolactone on scalp magnification counts, though not on photographs 4. The most common problem is a rise in liver enzymes, so doctors check liver blood tests before and during treatment 5 1. It can harm a developing baby, so it is not for women who are pregnant or could become pregnant without reliable contraception 6. It remains an off-label, specialist decision, usually after minoxidil and often after spironolactone.
How female pattern hair loss works
Female pattern hair loss is the most common cause of gradual thinning in adult women. Women usually keep the front hairline but notice a widening parting, more scalp showing over the crown and a thinner ponytail. Doctors grade it with the Ludwig or Sinclair scales 7 8. See the Ludwig scale.
Underneath the visible change is a disturbance of the hair cycle. A healthy scalp hair spends several years in anagen, the growth phase, then a few weeks in catagen, a short transition, and a few months in telogen, the resting phase, before it sheds and a new hair starts. In pattern hair loss, susceptible follicles spend less time in anagen with each cycle. The follicle gradually shrinks, a process called miniaturisation, so each new hair is shorter, finer and lighter than the one before 8. Over years, thick terminal hairs are replaced by wispy vellus-like hairs, and the scalp shows through.
In men, androgens are the main driver. DHT, which is made from testosterone by the enzyme 5-alpha reductase, binds to androgen receptors in the dermal papilla, the control centre at the base of the follicle, and triggers miniaturisation. See DHT and hair loss. In women the picture is less tidy. Some women have clear signs of androgen excess, such as acne, excess facial hair, irregular periods or polycystic ovary syndrome. Many others have normal blood hormone levels and still develop pattern thinning, which suggests genetics, ageing, local sensitivity of the follicle and possibly oestrogen changes also matter 9. See PCOS and hair loss.
How bicalutamide works
There are two broad ways to reduce androgen action on the follicle:
- Reduce how much DHT is made. Finasteride and dutasteride block 5-alpha reductase. See finasteride for women.
- Block the receptor. Drugs such as spironolactone, cyproterone acetate, flutamide and bicalutamide sit on the androgen receptor so that DHT and testosterone cannot switch it on as easily.
Bicalutamide belongs to the second group. It is a pure, non-steroidal androgen receptor antagonist that acts mainly on peripheral tissues such as skin and hair follicles 1. Unlike spironolactone, it does not act on the mineralocorticoid receptor, so it does not raise potassium or lower blood pressure in the same way. Compared with flutamide, an older drug in the same family, it binds the receptor more strongly and has been described as having a better safety profile, particularly for the liver 10.
In theory, blocking the receptor lets the follicle spend longer in anagen and slowly reverse some miniaturisation. In practice, this happens slowly, so the first sign is often less shedding rather than visibly thicker hair 11.
What the studies found
Early case series
- Spain, 2019. A pilot study gave 25 mg to 50 mg a day to 17 women with female pattern hair loss. Two had a mild, temporary rise in liver enzymes that did not require stopping 12.
- Australia, 2020. The largest series reviewed 316 women, average age about 49, who took 10 mg to 50 mg a day for an average of about six months. Almost all were also taking low dose oral minoxidil and over half were taking spironolactone, so only six used bicalutamide alone. Hair loss severity fell by 6.5% at 3 months, 17% at 6 months, 20.2% at 9 months and 28.9% at 24 months. Nine women had raised liver enzymes 5 1.
- Spain, 2020. A follow-up cohort of 44 women on 25 mg to 50 mg a day found mild, self-resolving liver enzyme rises in 5 women (11.4%) and no one stopped treatment. Among the 32 women treated for more than six months, Sinclair severity fell by an average of 27.5% 10.
These numbers look encouraging, but none of these studies had a placebo group and most women were on several treatments at once.
What reviews conclude
A systematic review published in 2025 in the journal JAAD Reviews, and highlighted by the Journal of the American Academy of Dermatology, found nine eligible studies with 494 women. Six were retrospective chart reviews, two were case series and one was a single case report. Bicalutamide was used together with other treatments in 97% of women. In female pattern hair loss, severity fell by 17% to 28.9% after at least 24 weeks. Side effects were reported in 11.9%, most often raised liver enzymes (4.9%), swelling of the legs or around the eyes, stomach upset and period changes 2. A dermatology review from India reached a similar conclusion: promising, off-label and in need of better trials 1.
Randomised trials
- Brazil, 2025. 74 women with female pattern hair loss received 1 mg oral minoxidil plus either 25 mg bicalutamide or placebo for 24 weeks. Hair density rose by 18.1 hairs per square centimetre with bicalutamide and 21.5 with placebo, with no meaningful difference, and photographs showed similar improvement in both groups 3. Other experts pointed out that 24 weeks is short for an anti-androgen and that the bicalutamide group did shed less 11.
- India, 2026. 204 women aged 18 to 50 were randomised to 50 mg bicalutamide or 100 mg spironolactone for 24 weeks. On trichoscopy, bicalutamide added about 5 hairs per square centimetre at the front compared with about 3 with spironolactone, and hair shafts thickened more. However, there was no clear difference between the groups in photographs or shedding scores. Side effects were reported in 11.7% on bicalutamide and 18.6% on spironolactone 4.
Head to head with spironolactone over two years
A 2024 retrospective study of 120 Indian women found greater improvement with 50 mg bicalutamide than with 100 mg spironolactone, both combined with 2% minoxidil 13. A larger 2026 study from Madrid followed 187 women for 24 months and found the opposite trend: both drugs helped, but 54.4% improved by at least one Sinclair grade on spironolactone compared with 37.3% on bicalutamide, and bicalutamide needed closer laboratory monitoring 14. Taken together, neither drug is clearly superior, and the choice depends on the individual woman.
Other uses dermatologists explore
Low dose oral minoxidil often causes unwanted facial and body hair in women. A 2022 Australian review of 35 women found that adding bicalutamide reduced this side effect 15, and a 2026 Spanish report found both spironolactone and bicalutamide selectively reduced facial hair caused by oral minoxidil 16. Small reports have also described its use in adolescents with early female pattern hair loss 17 and in postmenopausal women 18. These are early findings, not established practice. See oral minoxidil for women.
Comparison table: options for female pattern hair loss
| Option | How it works | Evidence in women | Key cautions |
|---|---|---|---|
| Topical minoxidil | Lengthens anagen and enlarges follicles | Strongest, from many randomised trials | Early shedding, scalp irritation, facial hair |
| Low dose oral minoxidil | Same action, taken by mouth | Growing, including randomised data | Facial hair, fluid retention, faster heart rate |
| Spironolactone | Blocks androgen receptor, also a diuretic | Small trials and long clinical experience | Not in pregnancy, potassium and blood pressure |
| Bicalutamide | Pure androgen receptor blocker | Case series, two randomised trials, mixed | Liver enzymes, not in pregnancy, off-label |
| Finasteride | Lowers DHT production | Mixed, uncertain at 1 mg | Not in pregnancy, off-label |
| Low level laser therapy | Light energy to the follicle | Mixed results | Time, cost, device quality |
Sources for the table: 19 20 2 3 4 8. See also minoxidil for women and oral minoxidil.
Who a dermatologist might consider
Based on the published experience, bicalutamide is most often discussed for:
- Women with confirmed female pattern hair loss who have not improved enough with minoxidil.
- Women with signs of androgen excess, such as PCOS, acne or excess facial hair. Over half of the women in the reviewed studies had these features 2.
- Women who could not tolerate spironolactone, for example because of dizziness, low blood pressure or high potassium 13.
- Women on oral minoxidil who are bothered by facial hair 15.
It is usually not appropriate for women who are pregnant, trying to conceive or breastfeeding, women with liver disease, and women taking certain medicines that interact with it, including warfarin and some statins 6. Women with a history of hormone-related gynaecological cancer need specialist advice, because long-term safety data for anti-androgens other than spironolactone are limited in this group 21. It does nothing for hair loss caused by iron deficiency, thyroid disease, telogen effluvium or alopecia areata 22.
Safety: liver, pregnancy and other side effects
Liver. Raised liver enzymes are the side effect that matters most. In the reviewed studies they affected around 5% of women overall, usually mildly and often settling without stopping, though some women did stop 2 5. Reviews advise a liver blood test before starting and repeat tests during treatment, more often in the early months 1. Symptoms that need urgent medical review include nausea, vomiting, stomach pain, unusual tiredness, loss of appetite, dark urine and yellowing of the skin or eyes 1.
Pregnancy. The product information states that bicalutamide is only for use in men and can cause abnormalities in the fetus if taken in pregnancy 6. Any woman who could become pregnant needs reliable contraception throughout treatment and should ask her doctor how long to wait after stopping.
Other effects. Reported side effects include leg or eyelid swelling, stomach upset, breast tenderness, period changes and, rarely, low mood 5 2. A rise in blood lipids has been described, particularly in women with PCOS or existing metabolic problems, so cholesterol checks may be added 1. Bicalutamide also interacts with several medicines, so bring a full list, including supplements, to every appointment 6.
Step by step: what to expect
- Diagnosis first. A doctor confirms pattern hair loss, often with trichoscopy, and rules out other causes 22. See scalp analysis.
- Blood tests. Iron stores, thyroid function and hormone tests where there are signs of androgen excess, plus baseline liver tests if bicalutamide is being considered. See blood tests for hair loss and ferritin and women's hair loss.
- Minoxidil usually comes first. It has the strongest evidence for women 19.
- A frank discussion. Off-label status, dose, contraception, liver monitoring and the uncertain evidence should all be explained before a prescription.
- Baseline photographs. Same light, same angles, the parting and the crown. See tracking hair loss with photos.
- First 3 months. Liver blood tests are repeated. Shedding may ease, but density rarely changes this early 5.
- 6 to 12 months. The first fair point to judge visible change. Studies saw most of the measured improvement between 6 and 24 months 5 11.
- Long term. Any benefit lasts only while treatment continues, and monitoring continues too.
Malaysian context
In Malaysia, bicalutamide is a prescription medicine, so the only safe route for hair loss is through a doctor, ideally a dermatologist, who can explain off-label use and arrange blood tests. Do not buy tablets from online marketplaces or overseas sellers. Products can be checked on the NPRA QUEST product search 23, and doctors can be checked on the Malaysian Medical Council register 24. No verified Malaysian price source exists for this treatment, so ask for the cost of consultations, blood tests and medicine in writing.
PCOS is a common reason for women's hair thinning, and women with PCOS often also deal with weight, insulin resistance and cholesterol issues, which is one more reason to have proper monitoring 25 1. Hot, humid weather, daily tudung wear, tight hairstyles and frequent heat styling can make thinning look worse without being the root cause. See hijab and hair loss.
For assessment, consider a dermatologist or an experienced hair care centre in Kuala Lumpur, Petaling Jaya, Penang, Johor Bahru or Sibu. See women's hair loss clinics in KL, women's hair loss in Penang, Johor Bahru and Sibu.
Common myths
- "Bicalutamide is proven to work better than everything else." The two randomised trials disagree, and a 24-month study found spironolactone did slightly better 3 14.
- "It is a cancer drug, so it must be dangerous at any dose." The hair loss studies used 10 mg to 50 mg a day and most side effects in women were mild, but liver monitoring is still essential 2.
- "If my hormone tests are normal, anti-androgens cannot help." Many women in the studies had normal hormone levels, though results vary 5.
- "I will see thicker hair in a month." Measurable change usually takes 6 to 12 months or longer 11.
- "Low dose means pregnancy is safe." It can harm a developing baby at any dose 6.
Practical checklist
- Confirm the diagnosis of female pattern hair loss with a doctor.
- Check iron, thyroid and, if relevant, hormone levels.
- Try or discuss minoxidil first.
- If bicalutamide is suggested, ask about dose, evidence, off-label status and how often liver tests will be done.
- Use reliable contraception if you could become pregnant.
- Tell your doctor about every medicine and supplement you take.
- Know the warning signs of liver problems and act on them quickly.
- Take baseline photos and review at 6 and 12 months.
- Buy medicines only through a doctor or registered pharmacy.
Summary
Bicalutamide is a pure androgen receptor blocker that has moved from prostate cancer care into specialist hair clinics overseas. In women with female pattern hair loss, case series report gradual improvement over months to years, usually alongside minoxidil 5 2. The randomised evidence is mixed, with one trial showing no added benefit over oral minoxidil and another showing modest advantages over spironolactone on magnified counts only 3 4. It requires liver monitoring, strict pregnancy precautions and a doctor's supervision. For most Malaysian women, the sensible order is a proper diagnosis, minoxidil, then a discussion with a dermatologist about whether spironolactone, bicalutamide or another option suits their situation. Results vary from person to person.
Frequently asked questions
What is bicalutamide?
It is a non-steroidal anti-androgen tablet that blocks the androgen receptor. It is licensed for prostate cancer, and some dermatologists use it off-label for female pattern hair loss 1 6.
Does bicalutamide work for female hair loss?
Case series report a 17% to 29% drop in hair loss severity after at least 24 weeks, mostly alongside other treatments. Randomised trials are mixed, so it is promising but not proven 2 3 4.
Is bicalutamide better than spironolactone?
Not clearly. One 2026 trial favoured bicalutamide on magnified hair counts only, while a 24-month study found more women improved on spironolactone 4 14.
What dose is used for hair loss?
Studies in women used 10 mg to 50 mg a day. The dose is a decision for a doctor who also arranges blood tests 2 5.
Why are liver tests needed?
Raised liver enzymes are the most common side effect, seen in about 5% of women in reviewed studies. Doctors test before starting and regularly during treatment 2 1.
Can I take bicalutamide if I might get pregnant?
Only with reliable contraception and a doctor's supervision. It can cause abnormalities in a developing baby and must not be taken in pregnancy 6.
How long before I see results?
Shedding may ease first. Visible change usually needs 6 to 12 months, and studies saw further improvement up to 24 months 5 11.
Can I buy bicalutamide online in Malaysia?
It is a prescription medicine. See a doctor, and check products on the NPRA QUEST search rather than buying from unverified sellers 23.
Sources
- PubMed (Aulakh and Mysore, J Cutan Aesthet Surg, 2025). Bicalutamide: A review, 2025. accessed 27 Oct 2026
- PubMed (Lipner, J Am Acad Dermatol, 2025). Highlights from JAAD Reviews: August 2025, Bicalutamide for female hair loss, 2025. accessed 27 Oct 2026
- PubMed (Libório et al., JAAD Int, 2025). Bicalutamide 25 mg combined with minoxidil 1 mg versus minoxidil 1 mg for female pattern hair loss: A randomized double-blind clinical trial, 2025. accessed 27 Oct 2026
- PubMed (Jha et al., Clin Exp Dermatol, 2026). Spironolactone vs. bicalutamide in female pattern hair loss: a randomized clinical trial, 2026. accessed 27 Oct 2026
- PubMed (Ismail et al., J Am Acad Dermatol, 2020). Safety of oral bicalutamide in female pattern hair loss: A retrospective review of 316 patients, 2020. accessed 27 Oct 2026
- MedlinePlus (US National Library of Medicine). Bicalutamide. accessed 27 Oct 2026
- PubMed. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex, Br J Dermatol, 1977. accessed 27 Oct 2026
- DermNet. Female pattern hair loss. accessed 27 Oct 2026
- PubMed. Female pattern hair loss: A comprehensive review, Dermatol Ther, 2020. accessed 27 Oct 2026
- PubMed (Fernandez-Nieto et al., J Am Acad Dermatol, 2020). Bicalutamide: A potential new oral antiandrogenic drug for female pattern hair loss, 2020. accessed 27 Oct 2026
- PubMed (Gil-Redondo et al., JAAD Int, 2025). Improvement of female pattern hair loss with bicalutamide: A time-dependent process, 2025. accessed 27 Oct 2026
- PubMed (Fernandez-Nieto et al., Dermatol Ther, 2019). Oral bicalutamide for female pattern hair loss: A pilot study, 2019. accessed 27 Oct 2026
- PubMed (Jha et al., Australas J Dermatol, 2024). Efficacy and safety of spironolactone versus bicalutamide in female pattern hair loss: A retrospective comparative study, 2024. accessed 27 Oct 2026
- PubMed (Gil-Redondo et al., Dermatol Ther (Heidelb), 2026). Spironolactone versus Bicalutamide for Female Pattern Hair Loss: A 24-Month Unicenter Retrospective Comparative Study of Effectiveness and Safety, 2026. accessed 27 Oct 2026
- PubMed (Moussa et al., J Am Acad Dermatol, 2022). Bicalutamide improves minoxidil-induced hypertrichosis in female pattern hair loss: A retrospective review of 35 patients, 2022. accessed 27 Oct 2026
- PubMed (Jimenez-Cauhe et al., J Eur Acad Dermatol Venereol, 2026). Spironolactone and bicalutamide selectively reduce facial hypertrichosis induced by low-dose oral minoxidil, 2026. accessed 27 Oct 2026
- PubMed (Yoong et al., J Am Acad Dermatol, 2025). Combination of oral minoxidil and bicalutamide for the treatment of female pattern hair loss in adolescents, 2025. accessed 27 Oct 2026
- PubMed (Ferrer Guillén et al., Actas Dermosifiliogr, 2026). Efficacy and Tolerability of Oral Bicalutamide in Forty Postmenopausal Women With Female Pattern Hair Loss: A Retrospective Study, 2026. accessed 27 Oct 2026
- PubMed. Interventions for female pattern hair loss, Cochrane Database Syst Rev, 2016. accessed 27 Oct 2026
- PubMed. The Efficacy and Safety of Oral and Topical Spironolactone in Androgenetic Alopecia Treatment: A Systematic Review, Clin Cosmet Investig Dermatol, 2023. accessed 27 Oct 2026
- PubMed (Seyed Jafari et al., J Clin Med, 2024). Safety of Antiandrogens for the Treatment of Female Androgenetic Alopecia with Respect to Gynecologic Malignancies, 2024. accessed 27 Oct 2026
- American Academy of Dermatology. Hair loss: Who gets and causes. accessed 27 Oct 2026
- National Pharmaceutical Regulatory Agency (NPRA), Malaysia. QUEST 3+ Product Search. accessed 27 Oct 2026
- Malaysian Medical Council. Malaysian Medical Council (registered medical practitioners and specialists). accessed 27 Oct 2026
- NHS. Polycystic ovary syndrome (PCOS / PMOS). accessed 27 Oct 2026
Educational content. Not medical advice.